View
230
Download
0
Category
Preview:
Citation preview
10th annual
21 - 23 March 2017Suntec Singapore Convention& Exhibition Centre, Singapore
In conjunction with
www.terrapinn.com/bioasia
Innovation. Commercialisation. Access
AGENDA ANNOUNCED
40+ COUNTRIES
2SUMMITS
4WORKSHOPS
2SITE TOURS
Contact Pinky Fadullon at (65) 6322 2738 or pinky.fadullon@terrapinn.com to discuss your participation options
Our Story
Vice President, Xeraya Biologics
A GREAT PLACE TO MEET PEOPLE IN THE INDUSTRY, TO GET CONNECTED AND TO LEARN ABOUT THE CURRENT TRENDS IN THE MARKET.”
“
Asia’s biopharma industry has evolved from a manufacturing destination to a go-to market for clinical development and a hotbed of innovation. Asia contains some of the world’s hottest pharma and biopharmaceutical markets on the planet, including China and Indonesia. Are you making the most of the opportunity?
Welcome to BioPharma Asia 2017.
From humble beginnings as BioMedical Asia in 2008, BioPharma Asia has served over to 20,000 attendees over the last 9 years.A true one-stop shop for all things biopharma, our 2017 program will be our best yet. Our premium conference tracks will explore innovation in drug discovery and development, commercial partnership strategies, clinical trial design and regulatory affairs, commercialization & marketing, manufacturing, supply chain and more. We’ll also be featuring our most comprehensive biotech pitching opportunities ever, in our dedicated Biotech Innovation track offering you the chance to hear from the latest innovators.
Visionary keynotes will lay the foundations for two days of intensive learning, discussion and networking. Leading C-Level executives will share case studies from across the world, ensuring you can learn from the best of the best, then you can spend time debating with them during the small-group roundtable sessions, so you have time to foster relationships and make new business contacts.
If you want to meet the key influencers and the true innovators of Asia’s biopharmaceutical industry, then this is the perfect platform.
Limited speaking slots available! Contact Emily Chong at (65) 6322 2339 oremily.chong@terrapinn.com for speaking opportunities.
PRE-CONFERENCE PROGRAM TUESDAY, 21ST MARCH 2017
Agenda at a Glance
Research/Academic Site TourManufacturing Technical SymposiumOrphan Drug Congress Asia
Biotech Bootcamp Part 1
Biotech Bootcamp Part 2
Pre-Event Networking Drinks Reception
DAY TWO THURSDAY, 23RD MARCH 2017
Keynote Plenary: Local Biotech & Pharma Focus
Exhibition Visit & Networking Refreshments
Exhibition Visit & Networking Lunch
Exhibition Visit & Networking Refreshments
Close of BioPharma Asia 2017
BIOTECH INNOVATION
Antibody Drug Conjugates & Derivatives
MEDICAL AFFAIRS
Stakeholder Engagement
CLINICAL TRIALS
Clinical Innovations
BIOLOGICS MANUFACTURING
Continuous Processing
Vaccines for Infectious Diseases Evidence & Decision Making Clinical Supply Quality & Safety
Stem Cells, Biomarkers & Gene Therapy Safety & Compliance Clinical Operations Analytical Development
Supply Chain Technical SymposiumManufacturing/Packaging Site Tour
DAY ONE WEDNESDAY, 22ND MARCH 2017
CLINICAL TRIALS
Clinical Development
Regulatory Affairs
SUPPLY CHAIN
Regulation
Technology
BIOTECH INNOVATION
Immuno-oncology
Therapeutic vaccines
Keynote Plenary: Digital Transformation in BioPharma
Exhibition Visit & Networking Refreshments
Exhibition Visit & Networking Lunch
Exhibition Visit & Networking Refreshments
Roundtable Discussion Session
Plenary: Asia Spotlight: Credibility & Patient Centricity
Networking Drinks Reception
MARKET ACCESS
Pricing & Reimbursement
Country Spotlights
BIOLOGICS MANUFACTURING
Next-Generation Biologics Products
Process Design & Development
BioPharma Asia Marketing Summit
Carl FirthChief Executive Officer
Aslan Pharmaceuticals (Singapore)
Silviu ItescuCEO and Managing Director
Mesoblast, Australia
Weng Si HoExecutive Director – Biomedical Sciences
Singapore Economic Development Board
Jun WangFounder, Executive DirectorBeijing Genome Institute
(BGI), (China)
Raman SrinivasanVice President andHead of Operations
Biocon, (Malaysia)
Shao Siong ChuaHead of ManufacturingBaxalta (Singapore)
Steven LeeGlobal Head,
Technical Operations Dr Reddy’s Laboratories,
(India)
Frederik AslundPatent Examiner
European Patent Office (Austria)
Sean WuXiong CaoVice President, Global Business Development
Simcere Pharmaceutical Group, (China)
Yariv Hefez VP Strategic Development,
Business Development, Portfolio Management and
Partnering (Biosimilar) Merck (Switzerland)
Manjunath RamaraoGlobal Director & Head,
Disease Sciences & Technology
Bristol Myers Squibb, (India)
Peter HoangSenior Vice President,
Business Development and Strategy
Bellicum, (USA)
Ajay GautamExecutive Director & Head,
Asia Pacific & Emerging Markets, Scientific Partnering
and Alliances Astra Zeneca (China)
Rubby ChawlaFounder and President
Indian Patients Society for Primary
Immunodeficiency, (India)
Jim Miller Vice President and Head Bioogics Drug Substance
Manufacturing Genentech, Roche (USA)
William ClaxtonDirector and Co-Founder Asia-Pacific Alliance
of Rare Disease Organization (APARDO)
Paolo RampichiniHead, Supply Chain Asia
PacificRoche (Singapore)
Stephen DunnRegional Director of Investigations, APAC
Sanofi Aventis, (Singapore)
Abhishek BhagatRegional Medical Director,
Consumer HealthMerck Pte Ltd (Singapore)
James GarnerChief Executive OfficerNovogen, (Australia)
Eddie TamHead of Scientific andClinical Procurement,Asia Pacific & Japan
Sanofi, (China)
Pierre WinnepennickxPresident, ISPE Asia Pacific
Dimiter DimitrovSenior Investigator, Head of Protein Interactions Section
NIH, (USA)
Satish JindalCEO
Allied-Bristol Life Sciences (USA)
Koichi MiyazakiSenior Director, Regulatory
Affairs Group, Asia Development Department,
R&D DivisionDaiichi-Sankyo (Japan)
Carlos PereiraSite Head, ManufacturingNovartis, (Singapore)
Churn-Shiouh Gau Chief Executive Director
Center for Drug Evaluation (Taiwan)
Hugh DavisVice President, Head, Biologics
Clinical Pharmacology and China Biologics Leader,
Biotechnology CoEJanssen, (USA)
Alan Bollard Executive Director
Asia-Pacific Economic Corporation (APEC)
Secretariat (Singapore)
Peter SenterVice President, ChemistrySeattle Genetics, (USA)
Nick EdeExecutive Director
Imugene (Australia)
Yee Leong TeohCEO
Singapore Clinical Research Institute,
(Singapore)
Stewart GearySenior Vice President, Chief
Medical Officer, General Manager, Corporate Medical
Affairs HeadquarterEisai Co. Ltd (Japan)
Shubhadeep SinhaAssociate VP and Head,
Clinical Affairs, Medical Affairs and Pharmacovigilance,
Global Operations Hetero Group, (India)
Donnie McgrathVice President,
Executive Director Bristol Myers Squibb,
(USA)
Paul KimCEO
Medivate Partners, (Korea)
Stefan HartDirector, New Venture
J&J Innovation Center, (Singapore)
Lucas ChanSite Head, Manufacturing
King’s College Hospital Clinical Research Facility,
(UK)
Abrar MirFounder and
Managing Partner Quadria Capital,
(Singapore)
Shailendra BajpaiRegional Medical Director,
Diabetes Asia Sanofi- Aventis,
(Singapore)
Badri RengarajanPresident
International Pemphigus & Pemphigoid Foundation,
(USA)
Oliver NicolaiSenior Manager, Logistics and
Supply chain APAC Celgene, (Singapore)
Arun MaseehVice President, Research, Cluster Head, Innovation
Cadila Pharmaceuticals, (India)
Roman IvanovR&D Director
BIOCAD, (Russia)
Peter CulpepperCFO, COO Provectus
Biopharmaceuticals, (USA)
Yoshiya OdaPresident, Biomarkers and
Personalised Medicine Eisai Inc, (USA)
Ariane M. DavisonDirector of CommercialisationPacific Gene Tech, (China)
Jeffrey ChuaProcurement TechOps
Cluster Lead Novartis, (Singapore)
Brian MinVice President,
Biosimilars Development Samsung Biologics,
(South Korea)
Liang SchweizerHead of Asian Cancer
Research for AP Research Sanofi, (China)
Bobby GeorgeVP and Head of
Regulatory Affairs Reliance Life sciences,
(India)
John LimExecutive Director, Duke-NUS
Centre of Regulatory Excellence (CoRE),
(Singapore)
G S ReddySenior Vice President
Indian Immunologicals Limited, (India)
Nikhil SinglaAssociate Director, Vaccine
R&D ProgramInternational AIDS
Vaccines Initiative (IAVI), (India)
Maggie LimClinical Compliance Director,
Asia Pac, Japan and EM GlaxoSmithKline,
(Singapore)
Contact Emily Chong at (65) 6322 2339 oremily.chong@terrapinn.com for speaking opportunities.Past Speakers
8.00
PRE-CONFERENCE PROGRAM
Registration
3-day conference pass holders can select 1 morning and 1 afternoon session or one of our full-day pre-event summits. The choice is yours!
PRE-CONFERENCE DAY TUESDAY, 21ST MARCH 2017 DAY 1 WEDNESDAY, 22ND MARCH 2017 1/4
WORKSHOP 1:BIOTECH BOOTCAMP
PART 1
WORKSHOP 3: BIOTECH BOOTCAMP
PART 2
Financing a cure: Getting your business plan and pitch book right, for successful fundraising.
In part 1, we explore how to increase your chances of fundraising success, including:
• Plan for success: What makes a strong business plan?
• How to value your biotech start-up
• Developing your story• Maximising your social media
presence • Protecting your IP• Making yourself stand out
from the crowd: How can you position
Primer in successful partnership management: Licensing, partnerships and strategic alliance management
In part 2, we talk partnerships and growth strategy
• What should you be looking for in your partners and how can you make your business more attractive to them?
• What makes a successful partnership?
• When do you build a board?• How do you meet your buy-
side customers • Getting your pitching strategy
right
WORKSHOP 2:MANUFACTURING
TECHNICAL SYMPOSIUM
SITE TOUR 2:MANUFACTURING/PACKAGING SITE
This workshop focuses on protein aggregation & characterization methods in downstream purification,, with issues including:
• Understanding protein aggregation mechanisms
• Identifying the key stages in protein characterization
• Exploring available downstream & purification techniques and how they impact output and efficiency
Stay tuned for details of ourexciting 2017 site tours.
SITE TOUR 1:EXPERIMENTAL
THERAPEUTICS CENTER, A*STAR
WORKSHOP 4:SUPPLY CHAIN TECHNICAL
SYMPOSIUM
Witness drug discovery capabilities in Asia by joining us at a site tour to Experimental Therapeutics Center (ETC), a member of Agency of Science, Technology & Research (A*STAR). From assay development, high throughput screening, medicinal chemistry and ADME/toxicology, scientists from ETC show you how Singapore translate early stage discoveries towards proof-of-concept and into diagnostic and research tools.
From risk management to supply chain security, this workshop provides you with case studies showing how to improve your supply chain efficiency. Key areas of discussion include:
• Compare and contrast real time track & trace methods
• How packaging facilities and solutions can impact supply chain efficiency
• The impact of emerging technologies
• Understand cross-Asia regulations and how you can remain compliant
BIOPHARMA ASIA MARKETING SUMMIT
From innovations in digital pharma marketing, to mobile patient engagement, to getting patient experience right, marketing strategies have never been more important to your biopharma business.
Join this one-day summit as our guest speakers explore innovations in healthcare marketing, including :
• Putting customer experience firmly on your biopharma agenda
• Getting multichannel marketing right
• How digital is enhancing patient experience
• New tools in patient recruitment
• Integrating digital marketing into your marketing strategy
• Making big data work for your marketing
• Going social: How can you effectively use social media in pharma marketing?
ORPHAN DRUGCONGRESS ASIA
Join governments, regulators, patient groups and orphan drug manufacturers at the one-day Orphan Drug Congress Asia as we plot the pathway to ensuring rare disease patients get proper medical care in Asia.
Key topics for discussion include:
• ASEAN Harmonization: How can we get there?
• If it’s good for them, it’s good for us: Reciprocal approval potential for orphan drugs in Asia
• The price is right: Pricing & reimbursement strategies and their impact on government budgets
• Trailblazers: Meet the countries who are supporting orphan drug access for their citizens and hear how they are doing it
• Getting there early: Early diagnosis potential through newborn screening
9.00
2.00
1.00 LUNCH & NETWORKING SESSION
7.00 END OF PRE-CONERENCE DAY
5.00 PRE-EVENT NETWORKING RECEPTIONJOIN US FOR A DRINK ON THE EVE OF THE CONFERENCE & EXHIBITION, AND GET A HEADSTART ON YOUR NETWORKING.
BIOTECHINNOVATION
IMMUNO-ONCOLOGY
This exciting new addition to BioPharma Asia 2017 will see 40 of Asia’s most exciting and
innovative biotechs offering 10-minute insights into their products, pipelines and their
pathway to commercialization.
Company presentation-ImugeneEliminating gastric cancer in Asia with B cell peptide immunotherapy – clinical update
Nick Ede, CTO, Imugene, Australia
Company presentation
From brand planning to drug pricing and reimbursement, market access remains a
major challenge for pharma companies. Learn from these speakers on how to get your products to the patients that need them, at the right price.
PANEL DISCUSSIONAsia’s market access landscape: Understanding the perspectives of payers, healthcare policy makers, pharma and patients• Exploring strategies to satisfy
healthcare needs by working closely with pharma, policy makers and payers
• Understanding key considerations and priorities from the payers’ perspective
• Formulating an efficient communication channel for building a sustainable healthcare environment
From clinical development, operations and supply to
regulatory affairs, explore the latest innovations and strategies
for getting your clinical trials right.
Key considerations in designing clinical trials protocols for pan-Asia clinical studies• Understanding key
opportunities in conducting clinical trials in Asia
• Discovering key preferred countries in conducting trials from pre-clinical, early phase to patient safety and consent
• Strategies for navigating Asia’s fragmented regulatory landscape
• Where are the next clinical trial hotspots in Asia?
Explore best practice strategies for your manufacturing activities
including process design, development & implementation, and the manufacturing of high quality emerging therapeutic
products
Keeping up with the production demands of an evolving portfolio in Asia• Understanding the
challenges associated with the biomanufacturing of an evolving portfolio
• Balancing flexibility, scalability and cost of manufacturing of emerging biological products
• Case study on manufacturing of immuno-oncology products
Major themes for this track include harmonization of Asia’s pharma supply chain regulation
and how new technology is making supply chain more transparent and efficient.
PANEL DISCUSSIONEstablishing coherent supply chain practices in Asia• Promoting free trade
movement to encourage trade and economic growth – where are we now and what’s next?
• Encouraging the alignment of regulations and standards to ensure hassle free movement of goods and people
• Overcoming IP, trade secret and safety regulation while opening borders
• Investigating the possibility of achieving coherency in border regulation and movement of goods with the Trans-Pacific Partnership Agreement.
MARKETACCESS
PRICING & REIMBURSEMENT
CLINICALTRIALS
CLINICAL DEVELOPMENT
BIOLOGICS MANUFACTURING
NEXT GENERATION BIOLOGICS PRODUCTS
SUPPLY CHAIN
REGULATION
09:00
09:05
09:10
10:10
10:30
11:30
09:40
BIOPHARMA ASIA 2017 PRELIMINARY PROGRAM
DIGITAL TRANSFORMATION IN BIOPHARAMA
EXHIBITION VISIT & NETWORKING REFRESHMENTS
The future of medicine and how it impacts patients, pharma, physicians and regulators. In the digital age, with technology changing so rapidly, how can we make sure that we are prepared for the future? This exciting opening address for BioPharma Asia 2017 will explore the most exciting trends, ideas and technologies driving the future of our industry, including practical advice on how you can brace your business for the times ahead.
Redesigning healthcare system with artificial intelligence Some believe that artificial intelligence (AI) will lead to the end of human race, but there are also very clear benefits that AI could bring to the biopharma industry. Besides crunching data more efficiently and helping facilitate healing, AI can help in cutting clinical trial costs and time, thereby quickening the drug development process and getting much-needed drugs to market faster. Find out how AI can help companies to improve profit margins and deliver personalised treatments to patients in this exciting keynote session.
Blockchain meets Biopharma: How to prepare for the global data evolutionWhen you hear blockchain, you don’t necessarily think biopharmaceuticals. But the applications of blockchain can do so much more than digital currency. For example, it can help to increase the efficiency of the drug development process, by providing better security and transparency. It allows you to indelibly record medicinal and genomic data to combat counterfeit pharmaceutical production and protect intellectual property. That’s just a few applications. Join us as we uncover more and also consider some of the potential challenges that could be created, for example, around compliance and privacy.
Chairman’s opening remarks
Organiser’s welcome remarks
DAY 1 WEDNESDAY, 22ND MARCH 2017 2/4 DAY 1 WEDNESDAY, 22ND MARCH 2017 3/4
Company presentation
Company presentation
Company presentation
Company presentation
Company presentation
Pricing strategies and key considerations for bringing drugs from red to blue ocean markets in Asia• Risk assessment and
management in post market drugs
• Discover strategies for accessing this market, and navigating the fragmented regulatory framework in Asia
• Opportunities for working with country regulators to harmonise general, locally-adaptable guidelines improving drug access for patients
Will performance-based reimbursement be the future scheme in Asia?• Discovering benefits
of performance-based patient access schemes, as an alternative to current reimbursement plans in countries across Asia
• Understanding the challenges in implementing risk sharing schemes in Asia
• Identifying key practices required for long term viability of performance based drug reimbursement
• Is a strategy like this even possible when multiple country regulators are involved?
Tackling infrastructure, site selection and regulatory barriers to conduct successful pan-Asia clinical studies• Overcoming key regulatory
barriers to successfully conduct trials in emerging countries
• Exploring clinical site alternatives without compromising clinical data quality
• Qualifying trial sites to fulfil study requirements
Meeting the needs of patients: Practical advice for clinical developers planning pan-Asia trials
• Ensuring patient centricity of your clinical practices, through close communication with CROs, trial sites and partners
• Building the optimal communication methods with patients, for example, setting up apps or dedicated call centres
• Working with patient advocacy groups to better understand patient needs
From Phase 1 to 4: Quality management in Pan- Asia clinical trials• Developing and executing
quality audit from Phase 1 to 4 trials
• Cross functional teams working in top line study data communication
• Ensuring compliance and adherence to relevant regulations in Asia
Integrating hybrid options in biomanufacturing: Economic and operational implications• Discovering the best strategy
for integrating disposable solutions in existing facilities
• Realising the need for flexibility and scalability of hybrid manufacturing system in producing emerging therapeutic products
• Practical advice for integrating hybrid systems in your manufacturing operations
Next generation processes: What model works the best in Asia?Compare and contrast the available full scale processing technologies, and discover what works the best for manufacturing next generation therapeutic products in Asia.
CASE STUDY: JHL fully single use facility in China to manufacture biosimilars and monoclonal antibodiesHear first-hand how one company approached creating a fully single use facility for manufacturing of their products.
Handling challenges raised from parallel imports • Understanding impact of
grey market imports in drug pricing and motivation to innovate in Asia
• Exploring various pricing strategies to overcome parallel import of genuine products
• Exploring repackaging requirements for none authorised distributor prevent patient misinformation
Emerging compliance supply chain requirements in Asia • Establishing collaborative,
enterprise wide process for communicating compliance requirements with suppliers
• Ensuring clear assignment of compliance execution ownership for compliance adherence to local regulations
• Using constant engagement and linkage of individuals throughout an organization to prevent delay and potential loss of sales and product obsolescence
11:50
12:10
12:30
IMMUNO-ONCOLOGYPRICING &
REIMBURSEMENT CLINICAL DEVELOPMENT
NEXT GENERATION BIOLOGICS PRODUCTS
REGULATION
Company presentation
Company presentation
Company presentation
Company presentation
Company presentation
Company presentation
Exploring country-specific market access strategies• Besides pricing and
reimbursement, what are the other factors in consideration when accessing a new market in Asia?
• Understanding the role of patient groups and the importance of patient-centric approaches in defining your access strategy
• Overcoming regulatory hurdles: How can we handle the fragmented regulatory structures?
• Licensing by reciprocity in Asia: Is it even possible?
Country update:
Singapore
Country update:
China
This session highlights country case studies to showcase
how pharma representatives plan their access strategies in
different countries
PANEL DISCUSSIONOvercoming registration and submission challenges in pan-Asia clinical studies• What has changed since last
year’s meeting?• How can RA representatives
be more effective in navigating through the fragmented SEA market?
• Exploring the possibility of using an adaptive regulatory submission system, customised from established markets
• Established vs. emerging markets in Asia
Faridah Aryani, Senior Principal Assistant Director, Pharmaceutical Services Division, Ministry of Health, Malaysia
Promoting regulatory innovation in Singapore and the rest of Asia• Understanding the need
for creating a simplified, innovative regulatory framework to support the exponentially-growing number of trials in Asia
• Strategies for improving regulatory expertise and cross-nation support for promoting regulatory policy innovation
• Discussing methods to remove or reduce regulatory complexity, and minimise the impact of regulatory diversity, to ensure timely access to safe, high quality therapeutic products
Overcoming regulatory restrictions in implementing new biomanufacturing processes• Understanding the regulatory
requirements for modifying bioproduction processes in their respective countries
• Discussing strategies for speeding up approval procedures to upgrade bioprocesses
• Is it worth the time and resources to upgrade existing manufacturing processing to continuous systems?
Process development preparation for effective technology transfer and operation• From R&D to manufacturing
operations, what are the considerations required to ensure smooth transfer?
• Evaluating critical aspects to evaluate to ensure event free manufacturing
• Discovering the importance of cross function communication to promote successful routine bioproduction
From clone to pilot plant scale up: Case study of developing a CHO cell culture platform for antibody productionThis presentation will explore steps in upscaling antibody production from clone to manufacturing scale, including process development, tech transfer and quality measurements
Improving supply chain agility with late stage customisation• Formulating strategies to
ensure optimal process flow • Exploring various options
to satisfy segmentation requirements with variable volumes and packaging needs
• Using late stage customisation to overcome country specific regulations and requirements
What’s next after 2D track and trace in supply chain security?• Strategies for preventing
counterfeiting • Overcoming existing
infrastructure limitations to fully utilise the potential of 2D barcoding in track and trace
• Exploring the possibility of using internet of things and smart sensing to build a more efficient supply chain
Innovate cargo monitoring and tracking for pharmaceutical products with IoT• Understanding the
infrastructure requirements for using IoT for supply chain in Asia
• Balancing cost and benefits in using IoT to ensure quality of products delivered
• Case study in Asia: Strides
14:20
14:40
15:00
THERAPEUTIC VACCINES COUNTRY SPOTLIGHTS REGULATORY AFFAIRSPROCESS DESIGN AND
DEVELOPMENT TECHNOLOGY
12:50 EXHIBITION VISIT & NETWORKING LUNCH
ROUNDTABLE DISCUSSION SESSION
DAY 1 WEDNESDAY, 22ND MARCH 2017 4/4
IPR in biosimilars development-opportunities and threats to innovation driven pharma• How do pharma companies
decide to go or not to go ahead with launching biosimilar products?
• How do pharma companies leverage on Asia landscape to maximise revenue?
• Should biosimilar industry be worried over AbbVie’s IPR success case vs Amgen in the US?
Conquering future challenges by strategic positioning of downstream processing With the aim of providing wider treatment access, new classes of therapeutic drugs with greater specifity and higher potency need to be manufactured, and in a flexible volume to cater to the needs of the population. This session will explore potential solutions for making drugs more ‘manufacturable’ from a downstream perspective.
Streamlining supply chain with Big Data• Discover how big data can
help you handle your supply chain more easily in Asia
• Understanding the benefits of using cloud, data and analytics to drive operational efficiencies
• Overcoming challenges in real time transmission of data into cloud storage
15:20
THERAPEUTIC VACCINES COUNTRY SPOTLIGHTS REGULATORY AFFAIRSPROCESS DESIGN AND
DEVELOPMENT TECHNOLOGY
15:40
16:20
EXHIBITION VISIT & NETWORKING REFRESHMENTS
Company presentation
Company presentation
Table 1Countries specific strategies in overcoming challenging green field regulatory landscape
Table 2Performance based reimbursement- Why and how can we do that?
Table 5Maximising production output: Quality approach
Table 9IPR and patent related issues in biosimilars development
Table 10Building sustainable innovation ecosystem in Asia
Table 3Globalizing Clinical Trial Operations – Asia’s emerging leadership roleRobert Bruno, Director, Japan Clinical Operations, AbbVie, Japan
Table 4Talent management and communication strategies in pharma landscape
Table 7Key considerations in implementing continuous single use platform in Asia production
Table 8IoT in pharma supply: Where are we now and what’s next?
Table 11Finding licensing and supply chain partner in Asia developing economy
Table 12Partnership models for biotech startup
Country update:
Indonesia
Country update:
Vietnam
17:40 NETWORKING DRINKS RECEPTION
ASIA SPOTLIGHT: CREDIBILITY & PATIENT CENTRICITY
17:00 Overcoming credibility issues in Asia clinical trials and manufacturing processesWith two third of world’s population residing in Asia, it is unsurprising that Asia is the next market where biopharma are investing to grow. However, plagued with scandals and quality issues, many small to mid-size overseas companies are hesitating to enter the value chain here. In this presentation, we explore how stakeholders in Asia can work together to produce higher quality results and products to regain global confidence in the region.
17:20 Keeping patient centricity as an intrinsic goal in Asia pharmaceutical companiesEveryone wants to be a part of the lucrative Asia pharma market, but how do we make sure that our company is innovative enough to keep out competitors, while keeping patients’ interest as the ultimate objective to deliver health and healing? In this session, we explore how you can use a patient centricity approach to differentiate your business operation from your competitors.
Table 6Strategies to overcome production challenges when starting new manufacturing project in AsiaShao Siong Chua, Production Lead (Site Expansion), BioProduction Operations, Novartis, Singapore
DAY 2 THURSDAY, 23RD MARCH 2017 1/4
ANTIBODY DRUG CONJUGATES AND DERIVATIVES
BIOTECHINNOVATION
This exciting new addition to BioPharma Asia 2017 will see 40 of Asia’s most
exciting and innovative biotechs offering 10-minute insights into their
products, pipelines and their pathway to commercialization.
Company presentation-Immunwork
Tse Wen Chang, Founder, Immunwork, Taiwan
Company presentation
Company presentation
Company presentation
Medical led stakeholder engagement: How can drug providers better interact with patients and healthcare professionals in Asia?• How can pharma providers better
engage patients and investigators by setting aside investigator led funding, education grant and trial grant bonds for quality studies?
• Discovering strategies in making patients the priority in medical communication
• Exploring options to provide support, sponsorship and resources to patient groups and care givers
Payer, policy maker and provider engagement• Exploring key relationship building
strategy in working with payers and policy makers
• Understanding the concerns and priorities of stakeholders when building relationships with the national guideline committees
• Country case studies: How to successfully engage stakeholders for medical studies and drug reimbursement conversations
Digitalising healthcare practices in clinical operations• Using cloud, analytics, and electronic
source to fast track studies and potentially even approval processes
• Redefining SOP in clinical operations to integrate technology into practices
• Discovering strategic plans to train staff in moving towards digitalised practices
Enabling remote monitoring in clinical studies• Discussing possible benefits in using
advanced sensing technology for off-site patient monitoring
• Understanding technology available in providing personalised care for patients
• Overcoming challenges to widely implement remote monitoring in Asian clinical studies
Using QbD as the core design principle in continuous processing• Overcoming regulatory uncertainties in
using continuous processing • Does continuous manufacturing really
help to reduce drug development and commercialisation costs?
• Navigating regulatory guidelines
Identifying production control attributes in upgrading batch to continuous bioproduction• Understanding the best design
principles to ensure a consistent flow of products
• Integrating robust process controls and monitoring systems in continuous design
• Adopting analytical technologies and mathematical modelling to facilitate the adoption of continuous processing
From evidence generation to scientific exchange and stakeholder
management, the role of medical affairs is comprehensive and increasingly important, as they bridge the gap
between R&D and commercial. This track allows medical affairs professional to
interact and share best practices to better engage key stakeholders in Asia
MEDICAL AFFAIRS
STAKEHOLDER ENGAGEMENT
From clinical development, operations and supply to regulatory affairs, explore the latest innovations and strategies for
getting your clinical trials right.
CLINICALTRIALS
CLINICAL INNOVATIONS
Explore best practice strategies for your manufacturing activities including process design, development & implementation, and the manufacturing of high quality
emerging therapeutic products
BIOLOGICS MANUFACTURING
CONTINUOUSPROCESSING
10:30
11:15
11:35
09:10
DIGITAL TRANSFORMATION IN BIOPHARAMA
From ideas to international success: A real breakthrough story brought to you by an Asian biotech company Starting from nothing to million dollar success, this biotech company currently employs thousands to benefit the healthcare industry. Hear from true blue biotech company in Asia on their success story in building the reach of their companies from domestic to international market
10:10 Strategies in providing affordable healthcare in developing countriesDeveloping countries are facing enormous challenges when it comes to dedicating natural funds and resources. In the dilemma between investing on more economy boasting industries, and providing better healthcare infrastructure and facilities for the people, the former often get more attention to promote overall growth of the country. In Asia, many countries depend on out-of-pocket to fund healthcare policies, the big question is, how can stakeholders work together in providing accessible and affordable healthcare in limited funding by the government and people to afford these services?
09:30 KEYNOTE PANEL: Big pharma perspective in driving Asia biopharma innovationWith the highest amount of resources which can be invested into operation, big pharma companies are in the best position to lead the industry direction. When making a key decision, it is important to understand the impact in organisation and industry wide. How can big pharma avoid being “too-big-to-fail” and lead the industry to be more innovative?
EXHIBITION VISIT & NETWORKING REFRESHMENTS
DAY 2 THURSDAY, 23RD MARCH 2017 2/4
INFECTIOUS DISEASESEVIDENCE AND DECISION
MAKINGCLINICAL SUPPLY QUALITY & SAFETY
Company presentation
Company presentation
Company presentation
Company presentationOrally-delivered antiviral protein for Dengue and Zika
Eng Hung Ung, CTO, BioValence, Malaysia
Company presentation
Company presentation
Company presentation
Company presentation
The patient advocate perspective: Working better with pharma and key stakeholders to provide better patient care• Exploring various working strategies
in pre-clinical execution phase collaboration to promote disease awareness
• Working with patient groups to deliver better treatment outcomes, i.e. creating patient registry for drug trial recruitment and outreach
• Understanding potential collaboration and partnership opportunities between pharma, patient advocacy groups and government units
From pre- to post- launch: Improving the role of medical affairs in product life cycle management• Understanding the different roles
of medical affairs personnel in reimbursed market
• Exploring how medical affairs personnel help in pharma marketing
• From design, execution and supporting investigator initiated studies, how can medical affairs better utilise the available clinical outcomes to convince stakeholders in reimbursement decisions?
Prabhuram Krishnan, Medical Director (South ASEAN) and Regional Medical Advisor (Oncology), Eli Lilly, Malaysia
Using evidence-based discussions to build pharma reputation and brand recognition• Discovering strategies to further
develop and translate worldwide evidence base for local applications
• Improving uniformity and consistency in local investigator led studies
• Navigating policy intervention in scientific, evidence based decision making processes
Generating real world evidence in APAC- key challenges and strategies• Discovering strategies to generate
real-world evidence with limited resources and infrastructure
• Understanding how data collected helps in supporting market access mission of medical affairs
• Using country-by-country approach to tailor strategies in decision making
Integrating emerging technology into an effective adverse reporting process• Understanding how improving current
legislation helps to improve medical communication with patients and physicians
• Exploring the benefits in keeping up to cloud technology and social media
• Discovering how pharma companies can leverage on latest technology to reduce drug misinformation
Innovation in action: Using remote sensing and IoT for stroke patient monitoring• Using IoT for real time patient
monitoring• Discussing infrastructure limitation and
potential solutions in overcoming these challenges
• Sharing case studies on using remote sensing for patient monitoring off-sites
The impact of globalisation on clinical supply in Asia • Overview of the diverse import/export
regulatory barriers for pan-Asia clinical trials operation and supply
• Working with CROs to implement best practices in clinical supply
• Showcasing economic value to local regulators to innovate clinical supply practices
Technology integration for end-to-end clinical supply• From drug ordering to inventory
management and product distribution, how can clinical operators simplify E2E clinical supply in Asia?
• Centralised vs country specialised: What is the best clinical supply structure for diversified Asia regulatory framework?
• Exploring how clinical data management helps in improving quality and accuracy of clinical logistics and delivery
Drawing the parallel between small and large molecules: What can we learn from our industry peers?• Understanding the requirements of
continuous bioprocessing• What can biologics manufacturing
learn from small molecules and formulations team to continuously process biological products
Continuous processing in Asia: A case study• What are the added benefits in
adopting continuous processing?• Compared to conventional
biomanufacturing, what are the additional precautions required for successful implementation?
• Moving forward, what’s next after continuous processing?
QbD and beyond- where are we now in Asia?• In some countries, QbD has been
listed as one of the requirements in the submission for approval. What is the status in Asia and how can manufacturers continuously innovate to improve production cost and quality?
• Identifying critical process parameters and critical quality attributes to ensure robust technology transfer
Ensuring excellent production quality of emerging therapeutic products• Discover GMP and cGMP guidelines in
manufacturing of novel biologics, i.e. biosimilars, in Asia
• Vendor selection and management: How do we measure the quality success of our vendors?
• China case study
11:55
12:15
13:50
12:35 EXHIBITION VISIT & NETWORKING LUNCH
14:10
DAY 2 THURSDAY, 23RD MARCH 2017 3/4
INFECTIOUS DISEASESEVIDENCE AND DECISION
MAKINGCLINICAL SUPPLY QUALITY & SAFETY
Company presentation
Company presentation
Company presentation
Company presentation
Adopting HEOR to balance short-term goals and long-term market access goals• Using HEOR to convince healthcare
authorities on drug functions and value• Key strategies for presenting
collected medical research data and demonstrate drugs value
• Discover the importance of HEOR in countries without a reimbursement framework
Key performance indicators in measuring the success of HEOR• How can companies prioritise HEOR
spending to best impact payers’ pricing decisions?
• Balancing financial and manpower investments to maximise the output of resources invested
• Promoting proper data analysis throughout the drug development process to ensure accurate communication with stakeholders
Clinical supply for rare disease studies• Clinical development plans in
supplying for rare disease studies• Discussing possible solutions for
minimising operational cost for orphan drugs investigation
• From patient recruitment to clinical supply, how CROs, pharma, patient groups and clinical supplier helps to promote orphan drugs development in Asia at potential minimal cost?
Improving clinical transparency, efficiency and visibility in clinical supply• Souring reliable clinical supply partners
in Asia • Discussing strategies for more
transparent financial assessment when working with hospitals and site administrators
• Building proper infrastructure support to improve clinical supply efficiency
Quality assurance and control requirements for cell therapy products• From facilities to equipment and
material, how do manufacturers make sure that cell therapy products are manufactured in well-controlled manner?
• Exploring how a risk-based approach helps in biomanufacturing QA measurements
• Deriving quality measurements to ensure compliance in upscaling from clinical stage
Optimising product and process parameters with Design of Experiment (DoE)• Using DoE as a compliment to QbD• Developing critical quality attributes in
process monitoring and validation• Modelling approaches to gain full
benefit of DoE in satisfying quality design and development activities
14:30
14:10
PLATFORM TECHNOLOGYCOMPLIANCE & PATIENT
CENTRICITYCLINICAL OPERATIONS ANALYTICAL DEVELOPMENT
Company presentation
Company presentation
Company presentation
Company presentation
Establishing the medical affairs role as a cornerstone to build trust in pharmaceutical industry• Discovering strategies to ensure
medical compliance within institution• Exploring ways in building strong,
multi-faceted medical affairs organisation to navigate global healthcare landscape
• Case study
Cultivating patient centricity in the evolving role of medical affairs• Strategies for implementing patient
centricity frameworks within pharma companies
• Crafting patient education and engagement programs in Asia
• Emphasizing data, quality and sincerity as integral core values in medical practices
Balancing cost and efficiency in performing quality clinical operations• Staffing and training strategies to
ensure quality clinical operations• Exploring possibilities in widely
implementing risk-based monitoring• Offsetting the limitation of on-site
monitoring with risk based monitoring
Conducting quality clinical trials in China, a case studyThe Chinese government has recently reformed its healthcare structure to improve quality of clinical trials and manufacturing. Find out more about the status quo of clinical operations in China and how global companies can help in ensuring quality operation by strictly enforcing GCP and other SOP in their respective team.
Maggie Lim, Director, AP Clinical Development QA, R&D, Global Quality Assurance APAC, Japan, EM, GSK, Singapore
Developing efficient analytical techniques from product development to manufacturing• Developing high stability indicating
assays• Coping with the latest configurations,
reagents and alternatives in method validation and performance
• Exploring automation as a method for streamlining QC processes and maintaining uniformity of analytical processes
Enhancing purification and analytical techniques in bispecific biologics production• Discussing the potential application
of using 2D liquid chromatography to characterise therapeutic proteins
• Developing critical attributes for deciding on the analytical techniques to be used in bioproduction
• Case study: Bispecific antibody production
15:40
16:00
15:10 EXHIBITION VISIT & NETWORKING REFRESHMENTS
Contact Emily Chong at (65) 6322 2339 oremily.chong@terrapinn.com for speaking opportunities.
DAY 2 THURSDAY, 23RD MARCH 2017 4/4
Company presentation
Company presentation
Company presentation
Company presentation Competency and compliance training of medical staff• Establishing guidelines and structures
to promote cross functional team working and communication
• Ensuring staff to adhere to required SOPs and comply with regulations
• Strategies in training medical affairs staff to adhere to consistent, high quality standards
Encouraging investigator-led studies in Asia • Understanding how investigator led
studies encourage drug access and reduce drug price in countries
• Providing easier access to drugs to encourage investigator led studies
• Establishing better reporting system by taking account of patient’s opinions
How can big pharma lead GCP implementation to promote quality clinical research in India? Clinical trials in India have been plagued with scandals due to lack of compliance and ambiguous guidelines. While the CDSCO is renewing its policy to promote quality trials in the country, local companies need to learn from their overseas counterparts to regain international confidence in the market. Find out how big pharma in India can help in leading GCP within the country.
Is Vietnam the next China in Asia?With the increasing labour cost and lack of IP protection in China, companies are shifting their focus to its neighbour: Vietnam. Home to over 80 million population with one of the least advanced healthcare infrastructure in Asia, Vietnam poses one of the highest potential in the eye of industry. Find out how pharma companies venture and overcome barriers in conducting trials in Vietnam from this session.
Biocomparability and stability studies in biosimilar production• Key characterisation techniques to
ensure biosimilar functionality • Discussing strategies to maintain
product quality in upscaling biosimilar• Exploring key assays techniques and
development for biosimilar testing
Host cell protein (HCP) characterisation and mass spectrometry strategies• Adding mass spectrometry as part of
the host cell protein workflow• Analytical strategies in HCP
identification and purification process• Developing quantitative MS/MS
methods to determine HCP levels
16:20
16:40
17:00 CLOSE OF BIOPHARMA ASIA 2017
PLATFORM TECHNOLOGYCOMPLIANCE & PATIENT
CENTRICITYCLINICAL OPERATIONS ANALYTICAL DEVELOPMENT
SEMINAR PROGRAM WEDNESDAY, 22ND MARCH 2017DAY 1
END OF DAY 1 SCIENTIFIC SHARING END OF DAY 1 TECHNICAL UNIVERSITY
INFECTIOUS DISEASES AUTOMATION
NEUROLOGY PROCESS DESIGN
BIOMARKERS AND PLATFORM TECHNOLOGY FACILITY DESIGN
10:00 Early treatment for chronic Hepatitis B infected patients Feedback system
13:00 Neuro stem cell research Filtration system
15:30Genetic marker research assay for Alzheimer disease risk assessment
HVAC/ Humidity measurements
10:30 Overcoming challenges in treating Tuberculosis in Asia Sensing techniques
13:30 Pre-clinical candidate in treating Autism Spectrum DisorderMichael Entzeroth, Chief Operating Officer, Cennerv Pharma, Singapore
Viral removal
16:00Next generation anti-viral protein in combating global infectious diseases
Clean room design
11:00Platform technology in infectious virus vaccine development- a case study
To be announced
14:003D neuro cell culture- Self organisation of polarised cerebellar tissue in 3D culture of human pluripotent stem cell
Chromatography
16:30
RetroMAD1 – broad spectrum orally-delivered antiviral protein therapeuticRetroMAD1 is made using recombinant E.coli and easy to upscale. It has very good safety characteristics and it can withstand digestive enzymes for 2 hours. It is absorbed into the blood within 30 minutes and has a 39% bioavailability in non-human primates. It has also been tested on a variety of RNA and DNA viruses in selected in vitro and in vivo models in shrimp, fish, cats, dogs and monkeys. Among the potential human viruses of interest where testing has been carried out are Ebola, Dengue and Zika.Eng Hung Ung, CTO, BioValence, Malaysia
Cleaning validation
11:30Discovering safety and effect novel dengue vaccines in Asia children
To be announced
14:30Minimising inflammation in brain to prevent development of Alzheimer disease
Culture and media
17:00 To be announced To be announced
RESEARCH SHOWCASE MANUFACTURING TECHNOLOGY SHOWCASE
This conference track showcases early R&D in vaccines, infectious diseases and imaging technology.
This conference track showcases manufacturing and analytical techniques updates.
SEMINAR PROGRAM THURSDAY, 23RD MARCH 2017DAY 2
END OF DAY 2 SCIENTIFIC SHARING END OF DAY 2 TECHNICAL UNIVERSITY
THERAPEUTIC VACCINES RAPID TOOLS
STEM CELLS & GENE THERAPY AGGREGATIONS & STABILITY
IMAGING & DRUG DELIVERY TECHNOLOGY FACILITY DESIGN
10:00Using virus-like vesicle-based therapeutic vaccine to treat diseases
Fast method to analyse multiple attributes of therapeutic antibodies
12:30Novel biomarkers of resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus.
Simultaneous detection of protein aggregation
10:30Using therapeutic vaccines to cure HIV- is that still of an interest after many disappointments?
High throughput screening for antibodies
13:00 Biomarkers for hormone receptor for breast cancer patients Forced degradation studies
15:30Emerging characterization tools for biocomparability, test methods and specifications
Nanotechnology in precision targeting on cancerous tumour
16:00 Targeted therapy and delivery system with light and DNA cages ICH guidelines, practical examples and discussions
11:00Replicating HBV specific immune response with monocyte in developing vaccine therapy
Rapid peptide mapping
13:30 Using biomarkers for targeted therapy and rare disease treatment Residual quantification with NMR
15:00
T-ETM pharmaceutical molecules with both targeting and effector functions for improved efficacy and safetyImmunwork develops T-ETM molecules containing both targeting (T) and effector (E) moieties for applications in cancer, autoimmune, infectious, and CNS diseases. The T and E modules, which are based on multi-arm linker units, are constructed separately and then joined together by click chemistry. Our T-ETM platform can produce ADCs with improved DAR, homogeneity, and manufacturing processes, and also bispecific and multi-specific antibodies with optimal valency of T and E elements.Tse Wen Chang, Founder, Immunwork, Taiwan
Defining critical quality attributes, control strategies and change management
11:30Novel vaccination strategy to leverage on mucosal immunity and induction of mucosal immune response in treating HPV infection
Low concentration dosage analysis
14:00 Using stem cell therapy to combat chronic infectious diseases To be announced
16:30 To be announced To be announced
RESEARCH SHOWCASE MANUFACTURING TECHNOLOGY SHOWCASE
This conference track showcases early R&D in vaccines, infectious diseases and imaging technology.
This conference track showcases manufacturing and analytical techniques updates.
To get involved in the conference programme, contact Pinky Fadullon at (65) 6322 2738 or pinky.fadullon@terrapinn.com
• CEO, CSO, and Head of BD from Asian biotechs
• Researchers & Scientists from universities
• Head of BD and R&D from pharma
• VCs and PEs
• Senior market analysts from big banks
INNOVATION & PARTNERING
• Process Engineers
• Supervisors
• Investigators
MANUFACTURING TECHNOLOGY SHOWCASE
• Researchers
• Professors / PhDs
• Scientists
• Principal investigators
RESEARCH & DEVELOPMENT
• Researchers
• Professors / PhDs
• Scientists
• Principal investigators
SUPPLY CHAIN & LOGISTICS
• Clinical Trial Managers
• Clinical Supply Chain Managers
• Clinical Outsourcing Managers
• Heads of R&D from Pharmas
CLINICAL TRIALS
• Heads of Upstream
• Heads of Downstream
• Process Engineers from Pharmas and Biotechs
• Heads of Manufacturing
• Heads of Operations
BIOLOGICS MANUFACTURING
• Departments and Ministries of Health
• Heads of Market Access / Pricing & Reimbursement
• Heads of Commericalisation
• Chiefs/VPs of Medical
• Medical officers
COMMERCIALIZATION &MEDICAL AFFAIRS
Attendee profile
USA
Europe
Australia & New Zealand
India & Middle East
Southeast Asia• Singapore
• Malaysia
• Thailand
• Indonesia
• Philippines
• Vietnam
North Asia• Japan
• Korea
• China
• Hong Kong
• Taiwan
10%
3%60%
2%
18%
7%
Contact Pinky Fadullon at (65) 6322 2738 or pinky.fadullon@terrapinn.com to discuss your participation optionsWho attends
SERVICE DRIVEWAY
ENTRANCE/EXIT
MTech
RESEARCHSHOWCASE
NETWORKING
BIOTECHINNOVATION
CLINICALTRIALS
BioMANUFACTURING
LUNCH
C02 D02B02
A06
B12
A09
A07
A05
A02
B08
D10
D14
D26
D18
D08
D12
E08
E12
C13
E16 F15
F06
F10
F08
F12
F14
F22
D21
D15
D20 E19
F24
D23
D17
D22 E21
F26
D25
D19
D24 E23
A04
B10
B03
C09
POD
POD
POD
POD
POD
POD
POD
POD
POD
POD
POD
POD
POD
POD
POD
POD
POD
POD
POD
POD
POD
POD
POD
POD
POD
POD
POD
POD
POD
POD
POD
POD
POD
POD
POD
POD
POD
POD
POD
POD
PODPOD
PODPOD
PODPOD
PODPOD
PODPOD
PODPOD
PODPOD
PODPOD
PODPOD
PODPOD
Supply Chain
Manufacturing
Clinical Trials
Market access & Medical Affairs
Biotech Innovation Showcase
EXHIBITION
Contact Pinky Fadullon at (65) 6322 2738 orpinky.fadullon@terrapinn.com to discuss your participation options
Escalators Lift Restrooms
• Investment banks/investment advisers
• M&A legal consultants
• Laboratory supplies & services
• Platform technology
• Drug delivery technologies
• Medical device and diagnostics companies
• Raw materials, ingredients and APIs
INNOVATION & PARTNERING
• Bioprocess solutions
• Single Use
MANUFACTURING TECHNOLOGY SHOWCASE
• Mass spectrometry
• Chromatography
• Lab equipment and technologies
• Lab services
• Consumables
RESEARCH & DEVELOPMENT
• Cold chain and logistics providers
• Express logistics providers
• Packaging
• 3 PL
• Warehouses
• Software technologies
• Forwarding
SUPPLY CHAIN & LOGISTICS
• CROs
• Clinical trial sites
• Regulatory Consultants
• Translation consultants
• Small-scale logistics & transportation
• Tools and equipment
• Forecasting
• Clinical supply chain and logistics
• Express logistics
CLINICAL TRIALS
• CMO
• Logistics & transportation
• EQM & Tools
• EQM distributors
• Culture media, sera and reagents
• Engineering companies and contractors
BIO-MANUFACTURING AND MANUFACTURING TECHNOLOGY
• Pricing & Reimbursement Experts
• Commercialization experts
• Forecasters
• Healthcare communication consultants
• Ad agencies
• Marketing/Medical affairs consultants
• Wholesale and retail pharmacies/distributors
COMMERCIALIZATION &MEDICAL AFFAIRS
Exhibition Opportunities
Available Booked/Reserved
Contact Pinky Fadullon at(65) 6322 2738 or
pinky.fadullon@terrapinn.com to discuss your
participation options
Partner with us 10ways to engage clients
EXHIBIT
Showcase your solutions and technology to over 2000 Asia’s leading bipharma industry leaders by taking a stand on the exhibition floor. Maximize your brand visibility by taking a stand at a prime location.
COCKTAIL RECEPTION
Maximize your networking opportunities by hosting the cocktail reception. Increase your brand exposure during the exclusive cocktail reception to attendees across verticals and regions.
LEAD GENERATION
This is a digital inbound marketing program that uses social marketing and CRM to create awareness for your product or services. It allows you to generate leads that you can add to your sales pipeline.
CASE STUDY PRESENTATIONS
Deliver your brand message and demonstrate your thought leadership on a chosen topic to your target audience, all gathered in one room.
AWARDS
Present an award to recognize your buyers for their contribution to the industry and be seen as the leading solution provider in your field.
WORKSHOPS
Host an exclusive workshop on a topic chosen by you for prequalified biopharma leaders. Engage your current clients and leave it up to us to promote this to your prospects!
ARRANGED MEETINGS
Let us reach out to your prospects and help you arrange private meetings on-site!
ROUNDTABLE DISCUSSIONS
Host a roundtable of up to 20 industry professionals around a key topic. The format is a really powerful forum to meet qualified, self-selected attendees to debate a problem they have, that you can solve.
BRAND AWARENESS
This event is already being marketed by us. The sooner you join the more exposure you will get, via our website and other digital channels, print media and online community. Associate your brand with Asia’s leading bipharma gathering, and place it alongside or even more prominently than your competitors’.
PANEL DISCUSSIONS
Sit alongside the biopharma industry leaders to discuss key challenges of the market on one of our panel discussions. There is no other opportunity as suitable to present how well your solutions can be adopted.
Benefits
Keynote Presentation
Conference Panel
Exhibition Presentation
Conference Track
1-to-1 Meetings
Private Luncheon
Workshop / Site Tour
Keynote Panel
Client Pass
Conference Roundtable
Lanyard/Conference bag
Conference Presentation
Exhibition Booth
Conference Pass
Cocktail Reception
Exhibition space
Title
Day 1 Morning
1 Panelist
1 Presentation
1 Track
15 Meetings
Yes
1 Panelist
20 Passes
1 Discussion
Yes
1 Presentation
72 sqm
15 Passes
$400 / sqm
Workshop or
Cocktail
1 Presentation
Yes
5 Passes
18 sqm
3 Passes
Yes
Associate
1 Presentation
2 Passes
1 Discussion
12 sqm
2 Passes
Silver
1 Panelist
1 Presentation
5 Passes
18 sqm
3 Passes
Gold
1 Presentation
3 Meetings
8 Passes
1 Presentation
24 sqm
5 Passes
Platinum
1 Panelist
1 Presentation
1 Track
7 Meetings
1 Panelist
10 Passes
1 Discussion
1 Presentation
36 sqm
8 Passes
Diamond
Day 2 Morning
1 Panelist
1 Presentation
1 Track
10 Meetings
Yes
1 Panelist
15 Passes
1 Discussion
1 Presentation
54 sqm
10 Passes
Diamond Sponsor
Exhibitors
Silver Sponsor
Associate Sponsor
2017 sponsors & exhibitors
The earlier you book, the more you’ll save.Your next step towards building an effective presence at the event begins now.
Contact Pinky Fadullon at (65) 6322 2738 or pinky.fadullon@terrapinn.com
Recommended